Schizophrenia Care in Rural America - Innovative Strategies for Improving Adherence and Outcomes in Community Mental Health Centers

Released On
July 2, 2018

Expires On
July 1, 2019

Media Type
Internet

Completion Time
60 minutes

Specialty
Psychiatry

Topic(s)
Schizophrenia

Scroll to the Bottom of this Information to Begin this Course

Jointly provided by Boston University and TALEM Health, in collaboration with the National Rural Health Association and Hill Country MHDD Centers.

 

This activity is supported by an educational grant from Otsuka America Pharmaceutical, Inc. and Lundbeck.

 

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)
  • Nurses — 1.0 contact hours of which 1.0 are eligible for pharmacology credit.

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This program is designed specifically for mental health professionals practicing in a rural health setting who are involved in the care of patients with schizophrenia and schizoaffective disorders.

Program Overview

Schizophrenia is a chronic, heterogeneous, and progressively disabling mental illness characterized by frequent relapses, persistence of symptoms, and substantial functional deficits. Despite pharmacologic advances, the treatment of schizophrenia remains a challenge and outcomes remain suboptimal. Major gaps in practice are evident at each point on the care continuum, including underuse of measurement-based approaches, inadequate treatment in the acute and maintenance phases, and poor medication adherence. Rural settings present unique challenges to management of schizophrenia as patients have limited access to mental health providers in addition to geographic and financial barriers to care. This online educational activity is designed to help mental health providers practicing in rural settings overcome barriers and achieve better outcomes for their patients with schizophrenia. Expert faculty will discuss the safety and efficacy of currently available antipsychotic agents, strategies for individualizing treatment and monitoring symptoms, and the role of long-acting injectables for promoting medication adherence.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply current guideline recommendations and available data to individualize treatment for patients with schizophrenia.
  • Review the mechanisms of action, safety, and efficacy of antipsychotic treatments for schizophrenia.
  • Use measurement-based strategies and tools to assess and manage patients with schizophrenia.
  • Evaluate nonpharmacologic and pharmacologic strategies for improving medication adherence in patients with schizophrenia.

Faculty

Leslie Citrome, MD, MPH

Clinical Professor of Psychiatry and Behavioral Sciences
New York Medical College
Valhalla, New York

Rajiv Tandon, MD

Professor of Psychiatry
University of Florida College of Medicine
Chief of Psychiatry
Malcom Randall Veterans Affairs Medical Center
Chief of Service
University of Florida Health
Gainesville, Florida

Physician Accreditation and Credit Designation Statements

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Boston University School of Medicine and Talem Health. Boston University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Boston University School of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Accreditation and Nursing Credit Designation Statements

This educational activity has been provided by Continuing Nursing Education Provider Unit, Boston University School of Medicine and jointly provided by Talem Health.

Continuing Nursing Education Provider Unit, Boston University School of Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Contact Hours: 1.0 of which 1.0 are eligible for pharmacology credit.

Disclosures of Conflicts of Interest

Boston University School of Medicine asks all individuals, and their spouses/partners, involved in the development and presentation of Continuing Medical Education (CME) and Continuing Nursing Education (CNE) activities to disclose all relevant financial relationships with commercial interests. This information is disclosed to CME activity participants prior to the start of the educational activity. Boston University School of Medicine has procedures to resolve all conflicts of interest. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.

Dr. Citrome

  • Consultant: Acadia, Alkermes, Allergan, Forum, Intra-Cellular Therapeutics for Psychopharmacology
  • Speaker: Acadia, Alkermes, Allergan, Janssen, Lundbeck, Merck, Neurocrine, Otsuka in Psychopharmacology
  • Stockholder: Bristol-Myers Squibb, Eli Lilly, J & J, Merck, Pfizer
  • Royalties: Wiley (Editor-in-Chief, International Journal of Clinical Practice), UpToDate (reviewer), Springer Healthcare (book).

Dr. Tandon (Co-Course Director)

  • No relevant financial relationships to disclose.

Planning Committee:

  • David C. Henderson, MD, CME Course Director, Boston University School of Medicine receives research grant support from Otsuka and Roche.

The other members of the Planning Committee have no relevant financial relationships to disclose.

  • Carol A. Cahill, PCNS, Nurse Advisor, Boston Medical Center
  • Carmela Townsend, DNP, MS/MBA, RN, Lead Nurse Planner, Boston University School of Medicine
  • Kristopher Steinke, MD, Medical Director, Hill Country MHDD
  • Joanna Krause, MPH, Grants Manager, Boston University School of Medicine, CME
  • Erica Rusie, PharmD, Senior Director, Scientific Affairs, Talem Health, LLC
  • Kristin Della Volpe, Medical Writer, Scientific Affairs, Talem Health, LLC
  • Eric VanStone, Principal, Talem Health, LLC

Disclosure of Unlabeled Use

The faculty members plan on discussing unlabeled/investigational uses of a commercial product.

Method of Participation

To receive credit, participants must view the entire activity and complete the post-test and evaluation. Participants who receive a score of 75% or better will receive CME/CNE credit. A certificate of credit will be available for immediate download to those who successfully complete the post-test and evaluation.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.

Disclaimer

ALL PROGRAMS, ACTIVITIES, AND MATERIALS PROVIDED BY BOSTON UNIVERSITY OFFICE OF CONTINUING MEDICAL EDUCATION OR ITS ASSOCIATES ARE PROVIDED ON THE CONDITION THAT THEY BE USED SOLELY FOR EDUCATIONAL PURPOSES BY QUALIFIED HEALTH CARE PROFESSIONALS. IN NO EVENT SHALL BOSTON UNIVERSITY BE LIABLE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE INFORMATION CONTAINED IN THE CONTINUING MEDICAL EDUCATION PROGRAMS, ACTIVITIES OR MATERIALS. IN NO EVENT SHOULD THE INFORMATION CONTAINED IN THE PROGRAM BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE. NO PHYSICIAN-PATIENT RELATIONSHIP IS BEING ESTABLISHED.

©Talem Health, LLC 2018. All Rights Reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Talem Health, LLC is prohibited.